Corbus Pharmaceuticals Holdings, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Corbus obtained FDA clearance for TEMPO-1 (n=250), a registrational Phase 3 trial of CRB-701 in second-line oropharyngeal cancer, with enrollment expected September 2026. CANYON-1 Phase 1b study of CRB-913 (obesity, n=240) concluded last patient visit; topline data expected September 2026. Company appointed Leonardo Viana Nicacio as Chief Medical Officer, Nishant Saxena as Chief Business Officer, and Brent Pfeiffenberger to Board. Q2 2026 net loss was $35.0M (vs. $17.7M in Q2 2025); operating expenses rose $17.0M, driven by $10.0M CRB-701 milestone payment. Cash position: $117.9M as of June 30, 2026, projected to fund operations into 2028.
Why this rating
Phase 3 FDA clearance and imminent Phase 1b readout are material clinical catalysts for ~$68M market-cap company. Two September milestones could validate pipeline value significantly. Leadership strengthening is positive. Burn rate acceleration ($17M/quarter) against $118M cash is manageable but material 2-year runway.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.